RV + BTZ treatment leads to significant reductions in MM tumor burden and superior OS. C57BL/6 wild-type recipient mice were injected with Vk12598 myeloma cells (8 × 105) IV and treated per the schematic in Figure 2A. Mice were bled weekly posttreatment and serum paraprotein was evaluated via high-resolution serum electrophoresis. (A) Left: M-spike changes in mice posttreatment from week W1 through W4. GEE analysis up to W3 indicated that cohorts of LV, LV + BTZ, DV + BTZ, and BTZ were different from the VC group at W2 and W3, but not at W1 (P < .05). DV vs VC showed no differences at all time points. GEE trend analysis of W1 through W4 data also indicated treatment groups were different (P < .05) from the VC group at W2, W3, and W4, but not at W1. Center and left: Mean M-spike data at weeks 3 and 4, respectively. (B) Kaplan-Meier survival plots of mice posttreatment. P < .00001, log-rank test.